92
Participants
Start Date
February 24, 2021
Primary Completion Date
February 28, 2029
Study Completion Date
February 28, 2029
HeartMate 3 TM Left Ventricular Assist System
The HeartMate 3 TM Left Ventricular Assist System will be implanted within 21 days of randomization.
Guideline Directed Medical Therapy
Patients randomized in the control group will continue their guideline directed medical therapy which comprises the following stable combination at the maximal tolerated dose of betablockers, Angiotensin-Converting-Enzyme-inhibitors or Angiotensin II Receptor Blockers or Angiotensin receptor Neprilysin inhibitor and Mineralocorticoid Receptor Antagonists and Sodium-GLucose co-Transporter-2 (SGLT2) inhibitors if tolerated.
RECRUITING
CHU Besançon, Besançon
RECRUITING
Hôpital Pneumologique et Cardiovasculaire Louis Pradel, Bron
RECRUITING
CHU Caen, Caen
RECRUITING
La Tronche Hospital / CHU Grenoble, La Tronche
RECRUITING
Arnaud de Villeneuve Hospital / CHU Montpellier, Montpellier
RECRUITING
CHU Rouen, Rouen
RECRUITING
CHU Tours, Tours
RECRUITING
CHRU, Institut Lorrain du Coeur et des Vaisseaux Louis Mathieu, Vandœuvre-lès-Nancy
Hospices Civils de Lyon
OTHER